Earnings ·
NeuroOne reports Q3 revenue of $2.0M, up 16%, with record gross margins of 59.9%
NMTCNEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies Corporation reported fiscal third quarter 2026 results ending June 30, 2026. Product revenue increased 16% year-over-year to $2.0 million, while product gross margins expanded to a record 59.9%. The company received $2.7 million in new product orders, growing its backlog to $1.7 million. Total operating expenses rose to $3.6 million, resulting in a net loss of $2.0 million, or ($0.23) per basic share. Cash and cash equivalents decreased to $2.0 million from $6.6 million at the start of the fiscal year. The company raised an additional $1.0 million via its ATM program subsequent to quarter-end. NeuroOne operates in the medical technology industry, developing minimally invasive surgical diagnosis and treatment solutions for neurological disorders.